Biotech Values

[ghmm]

In addition to Dew’s warnings on Biotech investing (points 1 and 5 are my favorite) one other thing that really made me wonder was it appeared the DNDN wasn’t ready to go with Provenge even if they got approval. I am not sure how common it is but if you have a great drug with Block-buster potential, not to mention some potential competitors with similar technology a couple years down the road wouldn’t you be ready for launch within lets say a month or two of approval? They seemed like they were no were close and the manufacturing/CMC issues noted by the FDA add support to that.

I am curious if people on this board think Provenge will ever make it to market or is the survival advantage too questionable?